Disclosed herein are chimeric receptors that comprise an extracellular domain and a cytoplasmic signaling domain, wherein the extracellular domain has a reduced binding activity to a wild-type Fc fragment； nucleic acids encoding such chimeric receptors, and immune cells expressing the chimeric receptors. Also disclosed are methods of using the chimeric receptors to enhance the efficacy of antibody-based immunotherapy, such as cancer immunotherapy.
